[Novel oral anticoagulants in non-valvular atrial fibrillation: How to improve its management in Spain].

Recent real-world data studies on the use of direct oral anticoagulants (DOAC) in patients with non-valvular atrial fibrillation, provide data on the use of different DOAC according to patient characteristics. The objective of this work was to elaborate on the suggestions on the use of DOAC based on evidence and clinical experience. A multidisciplinary panel of 8 experts developed the agreed content. The document was completed in 10 regional meetings with experts from different specialties. According to these contributions, the panel prepared the final suggestions. The final document includes the contributions generated throughout the entire process in 3 sections. The general conclusions / suggestions on the use of DOAC are detailed. Specific tips on the use of each DOAC are proposed, based on the specific clinical profiles of the patients. Finally, the limitations on the use of DOAC are defined, and a group of actions are proposed to improve the management of anticoagulation. It is necessary to overcome the clinical and administrative barriers that hinder the optimal use of DOAC, in order to improve the treatment of patients with non-valvular atrial fibrillation who require anticoagulation.

Informations de copyright

Copyright © 2018 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved.